Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remission

Journal of Translational Medicine

Jun Shi¹  Hui Wang¹  Sihong Liu¹  Yinghua Yuan¹  Yuanmei Zhai¹  Jing Zhang¹  Zhentian Wu¹  Yehua Yu¹ 

[1] Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

关键词: Acute myeloid leukemia;    Relapse;    Biopsy;    Bone marrow;   

Others  :  821974
DOI  :  10.1186/1479-5876-12-18

 received in 2013-08-16, accepted in 2014-01-17,  发布年份 2014

【 摘 要 】

Background

Bone marrow (BM) aspiration is largely used for relapse assessment in acute myeloid leukemia (AML). It remains unclear what roles that BM trephine biopsy plays on relapse assessment.

Methods

Bone marrow (BM) sections during complete remission (CR) from 60 acute myeloid leukemia (AML) patients were retrospectively analyzed. Computer image processing technology was performed for detection of the distance between precursors and endosteum, and density of precursors was also calculated under light microscopic image. Immunohistochemistry was used to identify the immunophenotype of clustered precursors.

Results

Except for single and double precursors, there existed clustered precursors of 3-5 cells during CR. Here, we demonstrated that clustered precursors, but not single and double precursors, were useful in risk factor of relapse. Area under the receiving operator curve (ROC) was of 0.007 (CI 95%, from 0.572 to 0.851). Using a standard cut-off value of >4.0/mm² for cluster density, early relapse was detected with a sensitivity of 51.5% and a specificity of 85.7%.

Multivariate Cox regression analysis revealed that clustered precursor is an independent risk factor for early relapse (Adjusted HR: 0.325, 95% CI: 0.156-0.679, p = 0.003).

Conclusions

Cumulatively, clustered precursors in BM sections during CR may serve as an independent risk factor of early relapse and poor outcome for AML patients in cluster density > 4.0/mm² in sections. Early aggressive interventions are needed to prevent hematologic relapse.

【 授权许可】

   
2014 Yu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJ, International BFM Study Group on Paediatric AML: Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol 2010, 148:768-776.
• [2]Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D, Kaspers GJ, Creutzig U: Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010, 24:1422-1428.
• [3]Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y, Shibayama H, Nakamae H, Mawatari M, Hatanaka K, Sunami K, Shimoyama M, Fujishima N, Maeda Y, Miura I, Takaue Y, Fukuda T: Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica 2010, 95:1857-1864.
• [4]Uhlman DL, Bloomfield CD, Hurd DD, Peterson BA: Prognostic factors at relapse for adults with acute myeloid leukemia. Am J Hematol 1990, 33:110-116.
• [5]Helgestad J, Rosthøj S, Johansen P, Varming K, Østergaard E: Bone marrow aspiration technique may have an impact on therapy stratification in children with acute lymphoblastic leukaemia. Pediatr Blood Cancer 2011, 57:224-226.
• [6]Gong X, Lu X, Wu X, Xu R, Tang Q, Xu G, Wang L, Zhang X, Zhao X: Role of bone marrow imprints in haematological diagnosis: a detailed study of 3781 cases. Cytopathology 2012, 23:86-95.
• [7]Islam A: Proposal for a classification of acute myeloid leukaemia based on plastic-embedded bone marrow biopsy sections. Leuk Res 1993, 17:421-427.
• [8]Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL: Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 1984, 58:217-225.
• [9]Verburgh E, Achten R, Maes B, Hagemeijer A, Boogaerts M, De Wolf-Peeters C, Verhoef G: Additional prognostic value of bone marrow histology in patients subclassified according to the international prognostic scoring system for myelodysplastic syndromes. J Clin Oncol 2003, 21:273-282.
• [10]Saad ST, Vassallo J, Arruda VA, Lorand-Metze I: The role of bone marrow study in diagnosis and prognosis of myelodysplastic syndrome. Pathologica 1994, 86:47-51.
• [11]Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia: Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
• [12]Xiao L, Luxi S, Ying T, Yizhi L, Lingyun W, Quan P: Diagnosis of unknown nonhematological tumors by bone marrow biopsy: a retrospective analysis of 10,112 samples. J Cancer Res Clin Oncol 2009, 135:687-693.
• [13]Wu H, Cao G, Li L, Shi J, International Conference on Multimedia Technology: ICMT 2010: Identifying Immature Precursor Cells in Bone Marrow Pathological Images Based on Distance Transform and Internal Structures of Cells. Ningbo: IEEEXplore; 2010.
• [14]Voulgarelis M, Giannouli S, Tasidou A, Anagnostou D, Ziakas PD, Tzioufas AG: Bone marrow histological findings in systemic lupus erythematosus with hematologic abnormalities: a clinicopathological study. Am J Hematol 2006, 81:590-597.
• [15]Lo Celso C, Fleming HE, Wu JW, Zhao CX, Miake-Lye S, Fujisaki J, Côté D, Rowe DW, Lin CP, Scadden DT: Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 2009, 457:92-96.
• [16]Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, Fukata M, Miyamoto T, Lyons B, Ohshima K, Uchida N, Taniguchi S, Ohara O, Akashi K, Harada M, Shultz LD: Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007, 25:1315-1321.
• [17]Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427-1434.
• [18]Casalou C, Fragoso R, Nunes JF, Dias S: VEGF/PLGF induces leukemia cell migration via P38/ERK1/2 kinase pathway, resulting in rho GTPases activation and caveolae formation. Leukemia 2007, 21:1590-1594.
• [19]Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000, 106:511-521.
• [20]Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D: Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 2010, 95:415-423.
• [21]Wu Z, Yu Y, Zhang J, Zhai Y, Tao Y, Shi J: Clustered immature myeloid precursors in intertrabecular region during remission evolve from leukemia stem cell near endosteum and contribute to disease relapse in acute myeloid leukemia. Med Hypotheses 2013, 80:624-628.
• [22]Paietta E: Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program 2012, 2012:35-42.
• [23]Hourigan CS, Karp JE: Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 2013, 10:460-471.